Erratum to: Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study

Ähnliche Einträge

• Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
  von: Mago, Rajnish, et al.
  Veröffentlicht: (2013)
• A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder
  von: Shiovitz, Thomas, et al.
  Veröffentlicht: (2014)
• Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder
  von: Freeman, Marlene P., et al.
  Veröffentlicht: (2016)
• A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder
  von: Gommoll, Carl P., et al.
  Veröffentlicht: (2014)
• Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials
  von: Sambunaris, Angelo, et al.
  Veröffentlicht: (2014)